Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00491283




Registration number
NCT00491283
Ethics application status
Date submitted
22/06/2007
Date registered
26/06/2007
Date last updated
28/01/2008

Titles & IDs
Public title
QuickVue Influenza A+B Clinical Field Trial
Scientific title
Comparison of Swab Types for Specimen Collection
Secondary ID [1] 0 0
CS-0119-08(B)
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Sensitivity and Specificity
Timepoint [1] 0 0
five months
Secondary outcome [1] 0 0
Sensitivity and Specificity
Timepoint [1] 0 0
Positive and Negative Predictive Values

Eligibility
Key inclusion criteria
Subjects must have:

* Fever (>38°C) (at time of visit or within the previous 48 hrs by history) and at least two of the following symptoms:

* Chills/sweats
* Cough
* Dyspnea (labored, difficult breathing)
* Fatigue
* Headache
* Myalgia (deep muscle aches)
* Nasal congestion
* Runny nose
* Sore throat
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients who are undergoing treatment with antivirals, now or within the last 7 days cannot be included in this study.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2006
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Sydney Airport Medical Centre - Mascot
Recruitment postcode(s) [1] 0 0
2020 - Mascot

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Quidel Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Andrew Keller, MD
Address 0 0
Sydney Airport medical Centre
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00491283